GNUV205 / GENUV - LARVOL DELTA

GNUV205, a bifunctional protein of engineered IL-2 fused with a novel anti-PD1 antibody, exhibits superior tumor suppressing efficacy in vivo (SITC 2023) - "Methods GNUV205 is an investigational immuno-cytokine molecule which comprises anti-PD-1 antibody (GNUV201) and engineered IL-2 (interleukin-2). We also confirmed GNUV205’s excellent tumor suppressing efficacy in other syngeneic tumor models such as B16F10 and Pan02. Conclusions In summary, these data strongly suggest that GNUV205 is a candidate-stage bifunctional immuno-cytokine for solid cancer therapy expected to overcome the limitations of current standard-of-care therapies, such as IL-2 or anti-PD-(L)1s."

Preclinical • Oncology • Solid Tumor • FCGR2A • FCGR2B • IL2 • IL2RG

Genuv Unveils GNUV205, a Bifunctional Fusion Protein That Potently Regresses Tumor Growth Without Toxicity (Businesswire) - "Genuv Inc...unveiled a new drug candidate, GNUV205, a fusion of engineered IL2 and anti-PD-1 antibody that advances immuno-oncology science. The drug candidate, for unspecified solid tumors, shows powerful anti-tumor activity without the toxicity typically associated with current IL-2 treatments....'Treatments targeting IL-2 are uniquely powerful, but have typically been plagued by systemic toxicity issues. Our strategy using a ‘no-alpha but attenuated beta gamma’ IL-2 variant fused with a unique anti-PD-1 via Genuv’s proprietary hetero Fc technology shows stronger binding affinity in the tumor microenvironment compared to marketed treatments Proleukine^®, Keytruda^® and Opdivo^® without Treg cell expansion'."

Pipeline update • Preclinical • Oncology • Solid Tumor